X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (244) 244
Publication (24) 24
Book Review (4) 4
Book / eBook (2) 2
Book Chapter (2) 2
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (186) 186
index medicus (129) 129
administration, oral (101) 101
male (87) 87
female (85) 85
dermatology (84) 84
oral bexarotene (69) 69
middle aged (65) 65
pharmacology & pharmacy (58) 58
adult (54) 54
oncology (52) 52
cancer (51) 51
aged (50) 50
bexarotene (46) 46
skin neoplasms - drug therapy (46) 46
t-cell lymphoma (44) 44
tetrahydronaphthalenes - therapeutic use (43) 43
treatment outcome (43) 43
retinoids (41) 41
tetrahydronaphthalenes - administration & dosage (41) 41
animals (39) 39
sezary-syndrome (33) 33
lymphoma, t-cell, cutaneous - drug therapy (32) 32
care and treatment (31) 31
therapy (31) 31
antineoplastic agents - therapeutic use (30) 30
cutaneous t-cell lymphoma (30) 30
mycosis fungoides (30) 30
mycosis-fungoides (30) 30
trial (28) 28
anticarcinogenic agents - therapeutic use (27) 27
antineoplastic agents (27) 27
antineoplastic agents - administration & dosage (27) 27
mycosis fungoides - drug therapy (27) 27
tetrahydronaphthalenes - adverse effects (27) 27
skin neoplasms - pathology (26) 26
clinical-trial (25) 25
drug therapy (25) 25
anticarcinogenic agents - administration & dosage (24) 24
dose-response relationship, drug (24) 24
double-blind (24) 24
health aspects (23) 23
research (23) 23
t cells (23) 23
aged, 80 and over (22) 22
chemotherapy (22) 22
antimitotic agents (21) 21
mice (21) 21
antineoplastic agents - adverse effects (20) 20
drug administration schedule (20) 20
medicine & public health (20) 20
non-hodgkin's lymphomas (20) 20
phase-ii (18) 18
anticarcinogenic agents - adverse effects (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
expression (17) 17
sezary syndrome (17) 17
apoptosis (16) 16
neoplasms - drug therapy (16) 16
retinoids - therapeutic use (16) 16
tetrahydronaphthalenes - pharmacology (16) 16
analysis (15) 15
chemoprevention (15) 15
drug therapy, combination (15) 15
lymphomas (15) 15
psoriasis (15) 15
dosage and administration (14) 14
isotretinoin (14) 14
mycosis fungoides - pathology (14) 14
neoplasm staging (14) 14
phase-ii trial (14) 14
retinoid (14) 14
sézary syndrome (14) 14
combination (13) 13
lymphoma (13) 13
review (13) 13
skin neoplasms - therapy (13) 13
antineoplastic agents - pharmacology (12) 12
breast-cancer (12) 12
drugs (12) 12
in-vitro (12) 12
prevention (12) 12
retinoic acid (12) 12
retinoid x receptors - agonists (12) 12
retrospective studies (12) 12
squamous-cell carcinoma (12) 12
targretin (12) 12
acid (11) 11
drug interactions (11) 11
efficacy (11) 11
follow-up studies (11) 11
hematology (11) 11
lymphoma, t-cell, cutaneous - pathology (11) 11
mycoses (11) 11
pharmacokinetics (11) 11
pharmacology/toxicology (11) 11
psoriasis - drug therapy (11) 11
sezary syndrome - drug therapy (11) 11
suberoylanilide hydroxamic acid (11) 11
toxicity (11) 11
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Dermatology, ISSN 0007-0963, 01/2013, Volume 168, Issue 1, pp. 192 - 200
Summary Background  Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors. It has... 
ORAL BEXAROTENE | TRIAL | THERAPY | EFFICACY | FENOFIBRATE | DOUBLE-BLIND | MYCOSIS-FUNGOIDES | STATIN | COMBINATION | HYPOTHYROIDISM | DERMATOLOGY | Amylases - blood | Skin Neoplasms - drug therapy | Humans | Clinical Protocols | Lymphoma, T-Cell, Cutaneous - drug therapy | Tetrahydronaphthalenes - adverse effects | Fenofibrate - therapeutic use | Musculoskeletal Pain - chemically induced | Thyrotropin - deficiency | Tetrahydronaphthalenes - administration & dosage | Anticarcinogenic Agents - administration & dosage | Adult | Female | Hypercholesterolemia - prevention & control | Anticarcinogenic Agents - adverse effects | Thyroxine - therapeutic use | Liver Function Tests | Drug Administration Schedule | Pancreatitis - chemically induced | Blood Cell Count | Pregnancy | Hypertriglyceridemia - prevention & control | Hypertriglyceridemia - chemically induced | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pregnancy Complications - chemically induced | Cholesterol, HDL - deficiency | Hypolipidemic Agents - therapeutic use | Pregnancy Complications - prevention & control | Blood Glucose - metabolism | Care and treatment | Prescription writing | Dermatology | Creatine kinase | Dermatologic agents | Triglycerides | Non-Hodgkin's lymphomas | Glucose | Hypothyroidism | T cells | Creatine | Dextrose | Amylases | Algorithms | Formulae, receipts, prescriptions | Thyroxine | Skin
Journal Article
Journal of Dermatological Treatment, ISSN 0954-6634, 07/2019, Volume 30, Issue 5, pp. 503 - 505
Journal Article
Nano Letters, ISSN 1530-6984, 2019, Volume 19, Issue 4, pp. 2231 - 2242
Journal Article
ACS Chemical Neuroscience, ISSN 1948-7193, 11/2013, Volume 4, Issue 11, pp. 1430 - 1438
Journal Article
OncoTargets and Therapy, ISSN 1178-6930, 02/2015, Volume 8, pp. 367 - 373
Cutaneous T-cell lymphoma (CTCL) is an umbrella term that encompasses a group of neoplasms that have atypical T-lymphocytes in the skin. Mycosis fungoides (MF)... 
CTCL | Retinoid | Cutaneous T-cell lymphoma | ORAL BEXAROTENE | CLINICAL-TRIAL | cutaneous T-cell lymphoma | EORTC | PHASE-II | T-CELL LYMPHOMA | retinoid | WORKING PARTY | CUTANEOUS-LYMPHOMAS | TASK-FORCE | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | CONSENSUS STATEMENT | MARROW TRANSPLANTATION | Sezary syndrome | Mycosis fungoides | Drug therapy
Journal Article